Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations

被引:3
|
作者
Thi Thu Nga Nguyen [1 ,2 ,3 ]
Rato, Sylvie [1 ]
Molina, Jean-Michel [1 ,2 ,3 ]
Clavel, Francois [1 ,2 ,3 ]
Delaugerre, Constance [1 ,2 ,3 ]
Mammano, Fabrizio [1 ,2 ]
机构
[1] INSERM, U941, F-75010 Paris, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, IUH, F-75475 Paris, France
[3] Grp Hosp St Louis, AP HP, F-75010 Paris, France
关键词
integrase strand transfer inhibitors; resistance mechanisms; evolution; TREATMENT-EXPERIENCED PATIENTS; OPTIMIZED BACKGROUND THERAPY; CO-FORMULATED ELVITEGRAVIR; DOUBLE-BLIND; INITIAL TREATMENT; TREATED PATIENTS; NAIVE ADULTS; INFECTION; EVOLUTION; INHIBITORS;
D O I
10.1093/jac/dku424
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: HIV resistance to the integrase inhibitor raltegravir in treated patients is characterized by distinct resistance pathways. We hypothesize that differences in the in vivo dynamics of HIV resistance to raltegravir are due to the genetic context of the integrase present at baseline. Patients and methods: We studied four patients whose viruses evolved towards different resistance pathways. The integrase baseline sequences were inserted into a reference clone. Primary resistance mutations were then introduced and their impact on viral replication capacity (RC) and resistance was measured. Results: Patients A and B experienced emergence and persistence of mutation N155H under raltegravir therapy. In the integrase sequence from Patient A, N155H conferred potent resistance coupled with a lower impact on RC than Q148H. In Patient B, instead, selection of N155H could be explained by the dramatic loss of RC induced by the alternative Q148H mutation. In Patient C, N155H initially emerged and was later replaced by Q148H. In this integrase context, N155H resulted in higher RC but lower resistance than Q148H. In Patient D, Q148H rapidly emerged without appearance of N155H. This was the only patient for whom Q148H conferred higher RC and resistance than N155H. Conclusions: The emergence of different resistance mutations in patients was in full agreement with the impact of mutations in different baseline integrase contexts. Evolution towards different resistance genotypes is thus largely determined by the capacity of different integrase sequences present at baseline to minimize the effect of mutations on virus RC while allowing expression of resistance.
引用
收藏
页码:731 / 738
页数:8
相关论文
共 50 条
  • [31] Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors
    Hu, Zixin
    Kuritzkes, Daniel R.
    JOURNAL OF VIROLOGY, 2014, 88 (16) : 9268 - 9276
  • [32] Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: A follow-up study
    Bittencourt Passaes, Caroline Pereira
    Guimaraes, Monick Lindenmeyer
    Cardoso, Sandra Wagner
    Pilotto, Jose Henrique
    Veloso, Valdilea
    Grinsztejn, Beatriz
    Morgado, Mariza Goncalves
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (12) : 1869 - 1875
  • [33] Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors
    Hassounah, Said A.
    Mesplede, Thibault
    Quashie, Peter K.
    Oliveira, Maureen
    Sandstrom, Paul A.
    Wainberg, Mark A.
    JOURNAL OF VIROLOGY, 2014, 88 (17) : 9683 - 9692
  • [34] Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience
    Garrido, Carolina
    Soriano, Vincent
    Geretti, Anna Maria
    Zahonero, Natalia
    Garcia, Silvia
    Booth, Clare
    Gutierrez, Felix
    Viciana, Isabel
    de Mendoza, Carmen
    ANTIVIRAL RESEARCH, 2011, 90 (03) : 164 - 167
  • [35] An HIV-1 integrase genotype assay for the detection of drug resistance mutations
    Hearps, Anna C.
    Greengrass, Vicki
    Hoy, Jennifer
    Crowe, Suzanne M.
    SEXUAL HEALTH, 2009, 6 (04) : 305 - 309
  • [36] Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors
    Ceccherini-Silberstein, Francesca
    Van Baelen, Kurt
    Armenia, Daniele
    Trignetti, Maria
    Rondelez, Evelien
    Fabeni, Lavinia
    Scopelliti, Fernanda
    Pollicita, Michela
    Van Wesenbeeck, Liesbeth
    Van Eygen, Veerle
    Dori, Luca
    Sarmati, Loredana
    Aquaro, Stefano
    Palamara, Guido
    Andreoni, Massimo
    Stuyver, Lieven J.
    Perno, Carlo Federico
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) : 3938 - 3948
  • [37] Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013
    Zoufaly, A.
    Kraft, C.
    Schmidbauer, C.
    Puchhammer-Stoeckl, E.
    INFECTION, 2017, 45 (02) : 165 - 170
  • [38] Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
    Malet, Isabelle
    Subra, Frederic
    Charpentier, Charlotte
    Collin, Gilles
    Descamps, Diane
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Delelis, Olivier
    MBIO, 2017, 8 (05):
  • [39] HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol
    Semengue, Ezechiel Ngoufack Jagni
    Santoro, Maria Mercedes
    Ndze, Valantine Ngum
    Dambaya, Beatrice
    Takou, Desire
    Teto, Georges
    Nka, Alex Durand
    Fabeni, Lavinia
    Wiyeh, Alison
    Ceccherini-Silberstein, Francesca
    Colizzi, Vittorio
    Perno, Carlo-Federico
    Fokam, Joseph
    SYSTEMATIC REVIEWS, 2020, 9 (01)
  • [40] Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
    Lopez, Pablo
    Tirado, Grissell
    Arias, Andrea
    Sanchez, Raphael
    Rodriguez-Lopez, Elliott R.
    Rivera-Amill, Vanessa
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (05) : 1 - 9